> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# PTC Therapeutics CEO Calls Sephience A 'Blockbuster' As Duchenne Drugs Lose Their Lift
- URL: https://www.bullished.co/ptc-therapeutics-ceo-calls-sephience-a-blockbuster-as-duchenne-drugs-lose-their-lift-1e28a2d5/
- Published: 2026-10-29T22:03:58.000Z
- Updated: 2026-10-29T22:03:58.000Z
- Description: Raised 2026 guidance of $960 million to $990 million in product revenue leans on Sephience, while Emflaza faces generic pricing.
- Author: Matteo Parrino
- Tags: Earnings, PTCT, Industry: Healthcare

[PTC Therapeutics](https://www.bullished.co/tag/ptct/), which develops and sells medicines for rare disorders, raised its 2026 product revenue guidance to [$960 million to $990 million](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financial-results-302924188.html?ref=bullished.co), and CEO Dr. Matthew Klein said on Thursday's earnings call that most of the lift comes from its phenylketonuria drug Sephience. The Duchenne muscular dystrophy franchise, he said, will not contribute as it did earlier in the year.

## Sephience carries the raise

Klein said the company now expects total revenue of [$1.29 billion to $1.32 billion](https://seekingalpha.com/news/4660845-ptc-therapeutics-gaap-eps-of-0%5F62-misses-by-0%5F76-revenue-of-358m-beats-by-52%5F99m?ref=bullished.co), and that the product guidance implies 64% to 69% year-over-year growth. Third-quarter total revenue was $358 million, including $276 million of product revenue, against $131 million of product revenue a year earlier, CFO Pierre Gravier said.

Sephience revenue was $182 million in the quarter, and [over 2,000 patients worldwide](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financial-results-302924188.html?ref=bullished.co) were on therapy as of September 30, Klein said. "All signs point to Safiance being a blockbuster rare disease product," he said, as transcribed, adding that management remains confident in a "2 billion plus" peak sales opportunity.

Klein put the U.S. runway at roughly 17,000 patients, most of whom have yet to try the drug. Between 2,000 and 2,500 remain on branded or generic Kuvan and are candidates to switch.

## Generics and a one-off Russian order

Asked what the higher guidance assumes, Klein said "The majority of that is driven by our enthusiasm for Suffiance," as transcribed. He said the Duchenne franchise, which has outperformed expectations this year, should not contribute as it did earlier in 2026.

On Emflaza, a new generic entrant "has brought down the price quite a bit," Klein said. Emflaza revenue was $25 million in the third quarter.

Translarna brought in $49 million, which included a Russian government purchase order Klein called "a bit unexpected." He said the company does not expect additional large government orders from Brazil or Russia in the fourth quarter.

## Cash and the Fabry deal

PTC ended September with $2.13 billion in cash and marketable securities, up from $1.95 billion at the end of 2025\. It bought a Fabry disease gene therapy, ST920, for $111 million upfront plus up to $100 million in milestones tied to U.S. approval. Klein said the company expects to finish its rolling approval submission in the fourth quarter and that the deal could add to earnings in 2027.

Management said it still expects to reach cash flow breakeven in 2026\. The company's market value was $5.3 billion after Thursday's session.

Klein said he will update investors on the rest of the pipeline in January.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [PTC Therapeutics GAAP EPS of -$0.62 misses by $0.76, revenue of $358M beats by $52.99M (NASDAQ:PTCT) | Seeking Alpha](https://seekingalpha.com/news/4660845-ptc-therapeutics-gaap-eps-of-0%5F62-misses-by-0%5F76-revenue-of-358m-beats-by-52%5F99m?ref=bullished.co) — seekingalpha.com
- [PTC Therapeutics: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/ptc-therapeutics-q3-earnings-snapshot/616-46a5766d-550b-46f6-b55d-8ebe58998f88?ref=bullished.co) — Associated Press
- [PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financial-results-302924188.html?ref=bullished.co) — prnewswire.com

### More on PTC Therapeutics

- [PTC Therapeutics Paid $19.3 Million Over Face To Settle Its Last Old Convertible Notes](https://www.bullished.co/ptc-therapeutics-paid-19-3-million-over-face-to-settle-its-last-old-convertible-notes-2a1a26b8/)
- [PTC Therapeutics Lifts 2026 Product Revenue Outlook To $960 Million-$990 Million After Sephience Sales Reach $181.9 Million](https://www.bullished.co/ptc-therapeutics-lifts-2026-product-revenue-outlook-to-960-million-990-million-after-109cb2aa/)

[All PTC Therapeutics (PTCT) coverage →](https://www.bullished.co/tag/ptct/)